Would lower than the current ApoB targets be more useful for clinical decision-making?Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).
CSI Rome Analysis of ApoB levels in the NHANES population revealed that guideline recommended ApoB targets have limited value in clinicial practice. Lotte Koopal and Gijs Berkelmans (both Utrecht, The Netherlands) discuss these insights with Dr. Seth Shay Martin (Baltimore, MD, USA) and Dr. Allan Sniderman (Montreal, Quebec, Canada).
- Currently recommended ApoB targets have little value for clinical decision-making 0:41
- Targets were originally set too high, and have never been reconsidered 2:16
- Which ApoB targets are useful in practice? 4:15
- ApoB: in addition to or replacing LDL measurement? 5:06
- Which targets should be mentioned in a next version of the guideline? 7:33
- Care would be better if guidelines responded to science quicker than they do now. 10:02
In the Cardiovascular Scene Investigation (CSI) series, young clinicians with an investigative mindset interview experts about the context and meaning of the results they just presented at the ESC congress.
The series is aimed to explore the background and practical implications of recent scientific developments, like those discussed in the Advances in Science session on 'Lipoproteins and real life: what the randomized clinical trials do not show us' at the ESC Congress 2016, with speakers in this session.
Faculty & Disclosures
Seth Shay Martin - Associate Director Lipid Clinic, Assistant Professor of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA
Allan Sniderman - Cardiologist, McGill University Health Centre, Montreal, Quebec, Canada
Lotte Koopal and Gijs Berkelmans - UMC Utrecht, The Netherlands
The speakers did not receive financial compensation for participating in these interviews